Track topics on Twitter Track topics that are important to you
Insmed Incorporated (NASDAQ: INSM) is a biopharmaceutical company engaged in the development and commercialization of drugs to treat patients with metabolic diseases that currently have limited treatment options. The company’s lead product, IPLEXTM, approved by the FDA in December 2005, is a composition of recombinant human IGF-1 and IGFbinding protein 3. IPLEXTM is now being studied as a treatment for several serious medical conditions, including two neuromuscular disorders, Myotonic Muscular Dystrophy (MMD) and ALS (Lou Gehrig’s Disease); HIV- Associated Adipose Redistribution Syndrome (HARS); and retinopathy of prematurity (ROP). Cumulatively, these disorders affect more than 100,000 patients in the United States, and an equal number in the European Union. Insmed is also developing novel products for the treatment of cancer. INSM-18 and rhIGFBP-3 are promising potential novel treatments for a variety of cancer types. Preclinical models demonstrate that both treatments interact with the IGF system to reduce tumor growth. Headquartered in Richmond, Virginia, Insmed maintains a state-of the-art FDA-approved biologic commercial manufacturing facility, Insmed Therapeutic Proteins, in Boulder, Colorado.
8720 Stony Point Parkway
United States of America
Brokerages expect Insmed, Inc. to report earnings of per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Insmed's earnings.
The share value of US rare diseases specialist Insmed more than doubled on Tuesday based on the top-line…
Insmed will commercialize ALIS, its inhaled amikaycin formerly known as Arikayce, on its own for a rare, bacteria-driven lung disease...
An inhaled antibiotic from Insmed (INSM) successfully treated patients with a rare lung disease caused by a bacterial infection, according to results from a phase 3 clinical trial reported Tuesday....
(Reuters) - Shares of Insmed Inc more than doubled on Tuesday after the company said its drug to treat adults with a rare lung disorder met the main goal in a key study, leading it to apply for accele...
Insmed will pursue accelerated approval for ALIS after its inhaled amikaycin, formerly known as Arikayce, met the primary endpoint in...
Insmed Inc said its drug for the treatment of a rare lung disorder met the main goal in a key study, sending its shares soaring in premarket trading on Tuesday. The drug, Alis, was used for the treatm...
Respiratory disease-focused Insmed Inc. netted $329mm through a follow-on public offering of 12.28mm common shares priced at $28.50 each. The company will use the funds for ongoing clinical trials of ...
The aim of this study is to investigate the safety and feasibility of daily subcutaneous injections of recombinant IGF1 complexed with IGF binding protein 3 (SomatoKine-INSMED) as a treatm...
Insmed Inc. is a biopharmaceutical company with unique protein development experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please ...
Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious lung diseases. Insmed is focused on the development and commercial...
Insmed Incorporated (NASDAQ: INSM) is a biopharmaceutical company engaged in the development and commercialization of drugs to treat patients with metabolic diseases that currently have limited treatm...
We have published hundreds of Insmed news stories on BioPortfolio along with dozens of Insmed Clinical Trials and PubMed Articles about Insmed for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Insmed Companies in our database. You can also find out about relevant Insmed Drugs and Medications on this site too.
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...